SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2021.01.11 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone - HTML (w)

2021.01.08 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) - HTML (w)

2020.12.21 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis - HTML (w)

2020.12.10 | 04:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Files New Drug Application for Aducanumab in Japan - HTML (w)

2020.11.27 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders - HTML (w)

2020.11.18 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) - HTML (w)

2020.11.16 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership - HTML (w)

2020.11.07 | 02:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease - HTML (w)

2020.11.03 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting - HTML (w)

2020.10.30 | 12:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease - HTML (w)

2020.10.06 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) - HTML (w)

2020.09.14 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health - HTML (w)

2020.09.11 | 14:01 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio - HTML (w)

2020.09.08 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS - HTML (w)

2020.08.07 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 / Doc nb : 118